As fear of a fifth wave stirs Europe, a backstage battle is brewing between two American Big Pharma, Pfizer and MSD (known as Merck in North America).
Both are preparing to market the first anti-Covid pills, much easier to administer than injection treatments.
These tablets will be given to the most vulnerable patients in the days following a positive test in order to avoid a severe form of the virus.
MSD, which has already suffered two setbacks on the front of anti-Covid vaccines, thought to hold its revenge with its drug, Molnupiravir, initially designed against the flu.
But, if he should be the first to arrive in French pharmacies by the end of the year, he will not be the only one.
Not content with having already established itself as the big winner of the pandemic with its vaccine ($ 36 billion in sales expected in 2021), Pfizer should also draw its miracle pill in the coming weeks,
This article is for subscribers only.
You have 75% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in